Umbrella Master Protocol: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYNOTE-U01)

Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Diagnostic Test: Tumor Imaging;   Procedure: Tumor Tissue Collection;   Procedure: Blood Sample Collection Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Atezolizumab;   Drug: Placebo;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Carboplatin Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Jankowska-Polańska B, Polański J, Chabowski M, Rosińczuk J, Mazur G Abstract The purpose of this study was to evaluate the influence of cognitive adjustment to cancer, assessed on the mini-Mental Adjustment to Cancer (mini-MAC) scale, on perception of anxiety and depression, assessed with the Hospital Anxiety and Depression Scale, in patients with non-small cell lung carcinoma (NSCLC). There were 185 patients, grouped according to the score of mini-MAC into constructive coping strategies, balanced coping strategies, and destructive coping strategies. We found that patients with predominantly destructive...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
ConclusionsAlthough cardiopulmonary complications can accompany salvage surgery, the procedure is generally safe. Survival outcome is encouraging, especially in cases with good response to initial treatment.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Conclusions: EGFR mutated in 10%, mostly in women and non-smokers, all of them adenocarcinoma. Low prevalence of the other mutations. Mutation of EGFR has better prognosis. In the multivariate analysis, the IVA vs IVB stage, ECOG, RT and treatment with ITK in mutated EGFR leads to a better prognosis.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Conclusion: Bronchoscopic re-biopsy for progressive lung cancer is feasible and safe. Histological change can be detected in a considerable number of patients, which is potentially valuable information for guidance of subsequent treatment.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Background: Atezolizumab (anti-PD-L1 antibody) can be used with anti-PD-1 antibodies (nivolumab and pembrolizumab) for treating NSCLC. The safety and efficacy of atezolizumab are unclear in patients who were previously treated with anti-PD-1 antibodies.Aim: To investigate the efficacy and safety of atezolizumab in patients who previously received anti-PD-1 antibodies.Methods: We retrospectively reviewed NSCLC patients who received atezolizumab after receiving anti-PD-1 antibodies. We evaluated tumour PD-L1 expression, cycles of anti-PD-1/PD-L1 antibodies, best response, progression free survival, and prior chemotherapies.R...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Conclusions: IPF is a risk factor for lung cancer development. Squamous cell carcinoma is the most common histologic subtype in patients with IPF. Large randomized controlled studies on the management of patients with IPF and lung cancer are sorely needed.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Idiopathic interstitial pneumonias Source Type: research
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Diagnostic Test: Tumor Imaging;   Procedure: Tumor Tissue Collection;   Procedure: Blood Sample Collection Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Biological: MK-7684 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study